Respirerx Pharma Inc (RSPI)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

126 VALLEY ROAD GLEN ROCK, NJ 07452

Cortex Pharmaceuticals' primary focus is to develop small molecule compounds that positively modulate AMPA-type glutamate receptors, a complex of proteins involved in the communication between nerve cells in the mammalian brain. These compounds, termed AMPAKINE compounds, enhance the activity of the AMPA receptor. These molecules are designed and developed as proprietary pharmaceuticals for the treatment of neurological and psychiatric diseases and disorders that are known, or thought, to involve depressed functioning of pathways in the brain that use glutamate as a neurotransmitter. Co.'s clinical compounds include CX717 and CX1739, both of which are in Phase II clinical.

Data as of 2020-05-30
Market Cap385.147 Thousand Shares Outstanding69.396 Million Avg 30-day Volume5.423 Million
P/E Ratio Dividend Yield EPS-0.54
Price/Sales Price cash flow ratio Price free cash flow ratio-1.1
Book Value-0.11 Price to Tangible Book-0.05 Alpha-0.06
Short Interest Ratio1.4 % Short Interest to Float0.6 R-squared4.2e-05
BETA0.046307 52-week High/Low0.85 / 0.0033 Stddev0.306199

Are you looking for this stock instead?

View SEC Filings from RSPI instead.

View recent insider trading info

Funds Holding RSPI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RSPI BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

STOLL ROGER G PHD

  • Director
9,309 2020-05-08 0

CASAMENTO CHARLES J

0 2020-04-06 0

LIPPA ARNOLD

  • Director
0 2020-04-03 1

MARGOLIS JEFF ELIOT SVP, CFO, SECRETARY & TEASURER

  • Officer
  • Director
  • 10% Owner
4,546,566 2020-03-22 1

SAPIRSTEIN JAMES PRESIDENT AND CEO

0 2019-10-08 0

DRAKE PETER F

  • 10% Owner
62,540 2019-05-09 0

WEINGARTEN ROBERT N

  • Director
652,500 2019-04-09 0

PURCELL RICHARD DAVID JR. SVP OF RESEARCH & DRUG DEVELOP

  • Officer
  • Director
0 2018-10-03 0

MACFARLANE KATIE

  • Director
0 2017-12-09 0

MANUSO JAMES S J PRESIDENT AND CEO

  • Officer
  • Director
74,252 2017-09-13 0

COLEMAN JAMES H SR. VP, BUSINESS DEVELOPMENT

  • Officer
0 2012-08-10 0

COTMAN CARL W

  • Director
0 2012-08-03 0

BENEDIK JOHN F

  • Director
0 2012-08-03 0

ALLNUTT ROBERT

  • Director
0 2012-08-03 0

JOHNSON M ROSS

  • Director
0 2012-08-03 0

HWANG MOOGAK

  • Director
0 2012-08-03 0

SAMYANG OPTICS CO., LTD

  • 10% Owner
6,765,466 2011-10-20 0

JOHNSON STEVEN ANDREW VP, PRECLINICAL DEVELOPMENT

  • Officer
0 2009-12-31 0

MESSINGER MARIA S CHIEF FINANCIAL OFFICER

  • Officer
0 2009-08-22 0

VARNEY MARK A PRESIDENT AND CEO

  • Officer
  • Director
0 2009-08-22 0

TRAN PIERRE V CHIEF MEDICAL OFFICER

  • Officer
0 2009-08-22 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions

Elevate your investments